Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 27, 2022

Investigational Drug Information for fluoruracil

✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for fluoruracil?

fluoruracil is an investigational drug.

There have been 29 clinical trials for fluoruracil. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1^st 2008.

The most common disease conditions in clinical trials are Breast Neoplasms, Colorectal Neoplasms, and Stomach Neoplasms. The leading clinical trial sponsors are University Hospital of Crete, Hellenic Oncology Research Group, and Gruppo Oncologico del Nord-Ovest.

Summary for fluoruracil

US Patents	0
International Patents	0
US Patent Applications	3,653
WIPO Patent Applications	2,246
Japanese Patent Applications	1
Clinical Trial Progress	Phase 3 (2008-03-01)
Vendors	5

Recent Clinical Trials for fluoruracil

Title	Sponsor	Phase
Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma	Kuwait Cancer Control Center	Phase 3
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Phase 1
Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients	Gruppo Oncologico Italiano di Ricerca Clinica	Phase 2

See all fluoruracil clinical trials

Clinical Trial Summary for fluoruracil

Top disease conditions for fluoruracil

Top clinical trial sponsors for fluoruracil

See all fluoruracil clinical trials

US Patents for fluoruracil

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Mallinckrodt

AstraZeneca

Colorcon

McKinsey

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.